Abstract
The prevalence of end-stage renal disease is increasing at an alarming rate. In 2000, chronic kidney failure developed in over 90,000 people in the United States; the current population of patients on dialysis numbers about 300,000, and 80,000 patients are living with transplanted kidneys. Both the prevalence and the incidence of end-stage renal disease are approximately twice what they were 10 years ago.1 Indeed, in 2000, the number of patients with newly diagnosed renal failure exceeded the number who died of any single type of cancer except lung cancer. Nephropathy due to type 2 diabetes accounts for almost all of . . .

This publication has 14 references indexed in Scilit: